BAYRYbenzinga

FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation

Summary

Bayer's Vitrakvi receives full FDA approval based on solid tumor data showing sustained efficacy in NTRK fusion-positive patients.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on April 10, 2025 by benzinga

    FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation | BAYRY Stock News | Candlesense